{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T11:36:19Z","timestamp":1778412979464,"version":"3.51.4"},"reference-count":175,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T00:00:00Z","timestamp":1664496000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01HL160472"],"award-info":[{"award-number":["P01HL160472"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL130871"],"award-info":[{"award-number":["R01HL130871"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U54HL142019"],"award-info":[{"award-number":["U54HL142019"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Oncolytics"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.omto.2022.09.009","type":"journal-article","created":{"date-parts":[[2022,10,2]],"date-time":"2022-10-02T10:01:37Z","timestamp":1664704897000},"page":"73-88","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Adding recombinant AAVs to the cancer therapeutics mix"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8528-5137","authenticated-orcid":false,"given":"Patrick L.","family":"Mulcrone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland W.","family":"Herzog","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9300-980X","authenticated-orcid":false,"given":"Weidong","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.omto.2022.09.009_bib1","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA. Cancer J. Clin."},{"key":"10.1016\/j.omto.2022.09.009_bib2","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA. Cancer J. Clin."},{"key":"10.1016\/j.omto.2022.09.009_bib3","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/ijc.31937","article-title":"Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods","volume":"144","author":"Ferlay","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.omto.2022.09.009_bib4","first-page":"7","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA. Cancer J. Clin."},{"key":"10.1016\/j.omto.2022.09.009_bib5","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.3390\/v13071205","article-title":"Harnessing the natural biology of adeno-associated virus to enhance the efficacy of cancer gene therapy","volume":"23","author":"Bower","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.omto.2022.09.009_bib6","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1080\/10717544.2016.1247926","article-title":"Seek and destroy: targeted adeno-associated viruses for gene delivery to hepatocellular carcinoma","volume":"24","author":"Dhungel","year":"2017","journal-title":"Drug Deliv."},{"key":"10.1016\/j.omto.2022.09.009_bib7","doi-asserted-by":"crossref","first-page":"E1889","DOI":"10.3390\/cancers12071889","article-title":"Towards clinical implementation of adeno-associated virus (AAV) vectors for cancer gene therapy: current status and future perspectives","volume":"12","author":"Hacker","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"2 Pt B","key":"10.1016\/j.omto.2022.09.009_bib8","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.canlet.2014.10.045","article-title":"Adeno-associated virus-mediated cancer gene therapy: current status","volume":"356","author":"Luo","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.omto.2022.09.009_bib9","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jconrel.2016.01.001","article-title":"Adeno-associated virus (AAV) vectors in cancer gene therapy","volume":"240","author":"Santiago-Ortiz","year":"2016","journal-title":"J.\u00a0Control Release."},{"key":"10.1016\/j.omto.2022.09.009_bib10","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/bab.2193","article-title":"Progress in gene therapy treatments for prostate cancer","volume":"69","author":"Xue","year":"2022","journal-title":"Biotechnol. Appl. Biochem."},{"key":"10.1016\/j.omto.2022.09.009_bib11","doi-asserted-by":"crossref","first-page":"119087","DOI":"10.1016\/j.lfs.2021.119087","article-title":"Recent trends in cancer therapy: a review on the current state of gene delivery","volume":"269","author":"Yahya","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.omto.2022.09.009_bib12","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1006\/viro.2001.1073","article-title":"Generation of a high-capacity hybrid vector: packaging of recombinant adenoassociated virus replicative intermediates in adenovirus capsids overcomes the limited cloning capacity of adenoassociated virus vectors","volume":"288","author":"Gon\u00e7alves","year":"2001","journal-title":"Virology"},{"key":"10.1016\/j.omto.2022.09.009_bib13","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/nrc.2016.63","article-title":"The genetics and mechanisms of T\u00a0cell acute lymphoblastic leukaemia","volume":"16","author":"Belver","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.omto.2022.09.009_bib14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.exphem.2021.12.191","article-title":"Recent advances in T-cell lymphoid neoplasms","volume":"106","author":"Bigas","year":"2022","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.omto.2022.09.009_bib15","doi-asserted-by":"crossref","first-page":"E3225","DOI":"10.3390\/cancers12113225","article-title":"Advances in acute myeloid leukemia: recently approved therapies and drugs in development","volume":"12","author":"Stanchina","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.omto.2022.09.009_bib16","doi-asserted-by":"crossref","first-page":"E7867","DOI":"10.3390\/ijms21217867","article-title":"Doxorubicin improves cancer cell targeting by filamentous phage gene delivery vectors","volume":"21","author":"Tsafa","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omto.2022.09.009_bib17","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1007\/s00432-010-0841-8","article-title":"The efficacy of combination therapy using adeno-associated virus-TRAIL targeting to telomerase activity and cisplatin in a mice model of hepatocellular carcinoma","volume":"136","author":"Wang","year":"2010","journal-title":"J.\u00a0Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.omto.2022.09.009_bib18","doi-asserted-by":"crossref","first-page":"107522","DOI":"10.1016\/j.pharmthera.2020.107522","article-title":"Acquired resistance to targeted therapies in NSCLC: updates and evolving insights","volume":"210","author":"Meador","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.omto.2022.09.009_bib19","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1158\/2159-8290.CD-21-0226","article-title":"Targeting EGFR exon 20 insertions in non-small cell lung cancer: recent advances and clinical updates","volume":"11","author":"Meador","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omto.2022.09.009_bib20","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","article-title":"Small molecules in targeted cancer therapy: advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.omto.2022.09.009_bib21","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1158\/2159-8290.CD-20-1808","article-title":"Therapeutic targeting of the tumor microenvironment","volume":"11","author":"Bejarano","year":"2021","journal-title":"Cancer Discov."},{"issue":"6 Suppl 16","key":"10.1016\/j.omto.2022.09.009_bib22","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/sonc.2002.37263","article-title":"Role of angiogenesis in tumor growth and metastasis","volume":"29","author":"Folkman","year":"2002","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.omto.2022.09.009_bib23","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ygyno.2014.07.105","article-title":"AAV-mediated persistent bevacizumab therapy suppresses tumor growth of ovarian cancer","volume":"135","author":"Xie","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.omto.2022.09.009_bib24","first-page":"687","article-title":"Tumor angiogenesis and anti-angiogenic gene therapy for cancer","volume":"16","author":"Li","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.omto.2022.09.009_bib25","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1479-5876-10-48","article-title":"New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer","volume":"10","author":"Stroncek","year":"2012","journal-title":"J.\u00a0Transl. Med."},{"key":"10.1016\/j.omto.2022.09.009_bib26","article-title":"Targeting the tumor microenvironment for improving therapeutic effectiveness in cancer immunotherapy: focusing on immune checkpoint inhibitors and combination therapies","volume":"1188","author":"Chyuan","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.omto.2022.09.009_bib27","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.omto.2022.09.009_bib28","doi-asserted-by":"crossref","first-page":"eabm1890","DOI":"10.1126\/sciadv.abm1890","article-title":"Leveraging gene therapy to achieve long-term continuous or controllable expression of biotherapeutics","volume":"8","author":"Cripe","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.omto.2022.09.009_bib29","first-page":"345","article-title":"Molecular cancer prevention: current status and future directions","volume":"65","author":"Maresso","year":"2015","journal-title":"CA. Cancer J. Clin."},{"key":"10.1016\/j.omto.2022.09.009_bib30","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/PPO.0000000000000348","article-title":"Optimizing immunomodulatory drug with proteasome inhibitor combinations in newly diagnosed multiple myeloma","volume":"25","author":"Ntanasis-Stathopoulos","year":"2019","journal-title":"Cancer J."},{"key":"10.1016\/j.omto.2022.09.009_bib31","first-page":"409","article-title":"Cancer Treatment and Survivorship Statistics","volume":"72","author":"Miller","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.omto.2022.09.009_bib32","doi-asserted-by":"crossref","first-page":"e35309","DOI":"10.1371\/journal.pone.0035309","article-title":"Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials","volume":"7","author":"Lovly","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.omto.2022.09.009_bib33","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s40670-021-01267-1","article-title":"Precision cancer medicine: dynamic learning of cancer biology in a clinically meaningful context","volume":"31","author":"Zivanov","year":"2021","journal-title":"Med. Sci. Educ."},{"key":"10.1016\/j.omto.2022.09.009_bib34","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/s41591-021-01462-y","article-title":"Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial","volume":"27","author":"Creelan","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.omto.2022.09.009_bib35","doi-asserted-by":"crossref","first-page":"104143","DOI":"10.1016\/j.ebiom.2022.104143","article-title":"Objective assessment of tumor infiltrating lymphocytes as a prognostic marker in melanoma using machine learning algorithms","volume":"82","author":"Aung","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.omto.2022.09.009_bib36","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13045-021-01085-3","article-title":"Immunotherapies targeting stimulatory pathways and beyond","volume":"14","author":"Marin-Acevedo","year":"2021","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.omto.2022.09.009_bib37","doi-asserted-by":"crossref","first-page":"899","DOI":"10.3390\/genes12060899","article-title":"Drugging the undruggable: advances on RAS targeting in cancer","volume":"12","author":"Molina-Arcas","year":"2021","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.omto.2022.09.009_bib38","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.3390\/jcm10173792","article-title":"Biologic and therapeutic implications of genomic alterations in acute lymphoblastic leukemia","volume":"10","author":"Iacobucci","year":"2021","journal-title":"J.\u00a0Clin. Med."},{"key":"10.1016\/j.omto.2022.09.009_bib39","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.semcancer.2019.12.012","article-title":"Drug repurposing for cancer therapy, easier said than done","volume":"68","author":"Gonzalez-Fierro","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.omto.2022.09.009_bib40","first-page":"317","article-title":"The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug","volume":"8","author":"Juarez","year":"2018","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.omto.2022.09.009_bib41","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1080\/13543784.2018.1471132","article-title":"Orlistat as a FASN inhibitor and multitargeted agent for cancer therapy","volume":"27","author":"Schcolnik-Cabrera","year":"2018","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.omto.2022.09.009_bib42","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/mt.2009.83","article-title":"Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T\u00a0cells and increased antileukemic efficacy in\u00a0vivo","volume":"17","author":"Milone","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omto.2022.09.009_bib43","doi-asserted-by":"crossref","first-page":"16756","DOI":"10.1021\/acsomega.9b01465","article-title":"Optimizing mannose \"click\" conjugation to polymeric nanoparticles for targeted siRNA delivery to human and murine macrophages","volume":"4","author":"Glass","year":"2019","journal-title":"ACS Omega"},{"key":"10.1016\/j.omto.2022.09.009_bib44","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.omtn.2022.01.006","article-title":"Ultrasound-mediated gene delivery of factor VIII plasmids for hemophilia A gene therapy in mice","volume":"27","author":"Song","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omto.2022.09.009_bib45","doi-asserted-by":"crossref","first-page":"13343","DOI":"10.3748\/wjg.v20.i37.13343","article-title":"Gene therapy in pancreatic cancer","volume":"20","author":"Liu","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.omto.2022.09.009_bib46","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1128\/CMR.00008-08","article-title":"Gene therapy using adeno-associated virus vectors","volume":"21","author":"Daya","year":"2008","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.omto.2022.09.009_bib47","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.immuni.2016.02.023","article-title":"Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T\u00a0cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.omto.2022.09.009_bib48","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","article-title":"Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T\u00a0cells","volume":"28","author":"Zhao","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omto.2022.09.009_bib49","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.2217\/imt.15.77","article-title":"Targeting B-cell maturation antigen in multiple myeloma","volume":"7","author":"Tai","year":"2015","journal-title":"Immunotherapy"},{"key":"10.1016\/j.omto.2022.09.009_bib50","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.omto.2022.09.009_bib51","first-page":"790","article-title":"Cytokine release syndrome after treatment of anti-CD19 CAR-T therapy with IL-6 knocking down in patients with central nervous system B-cell acute lymphocytic leukemia","volume":"51","author":"Mao","year":"2021","journal-title":"Ann. Clin. Lab. Sci."},{"key":"10.1016\/j.omto.2022.09.009_bib52","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T\u00a0cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.omto.2022.09.009_bib53","doi-asserted-by":"crossref","first-page":"6284","DOI":"10.1158\/1078-0432.CCR-20-0472","article-title":"Intratumoral IL12 mRNA therapy promotes TH1 transformation of the tumor microenvironment","volume":"26","author":"Hewitt","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omto.2022.09.009_bib54","doi-asserted-by":"crossref","first-page":"540","DOI":"10.3390\/pharmaceutics12060540","article-title":"Development of a DNA vaccine for melanoma metastasis by inhalation based on an analysis of transgene expression characteristics of naked pDNA and a ternary complex in mouse lung tissues","volume":"12","author":"Kodama","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.omto.2022.09.009_bib55","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.canlet.2012.11.016","article-title":"Development of an anti-angiogenic therapeutic model combining scAAV2-delivered siRNAs and noninvasive photoacoustic imaging of tumor vasculature development","volume":"332","author":"Ruan","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.omto.2022.09.009_bib56","doi-asserted-by":"crossref","first-page":"182","DOI":"10.5732\/cjc.010.10074","article-title":"Advancement and prospects of tumor gene therapy","volume":"30","author":"Zhang","year":"2011","journal-title":"Chin. J. Cancer"},{"key":"10.1016\/j.omto.2022.09.009_bib57","doi-asserted-by":"crossref","first-page":"e66315","DOI":"10.1371\/journal.pone.0066315","article-title":"Real-time monitoring of miRNA function in pancreatic cell lines using recombinant AAV-based miRNA Asensors","volume":"8","author":"Chen","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.omto.2022.09.009_bib58","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41434-020-0140-1","article-title":"AAV3-miRNA vectors for growth suppression of human hepatocellular carcinoma cells in\u00a0vitro and human liver tumors in a murine xenograft model in\u00a0vivo","volume":"28","author":"Yin","year":"2021","journal-title":"Gene Ther."},{"key":"10.1016\/j.omto.2022.09.009_bib59","doi-asserted-by":"crossref","first-page":"8875","DOI":"10.3390\/ijms23168875","article-title":"Transcript-targeted therapy based on RNA interference and antisense oligonucleotides: current applications and novel molecular targets","volume":"23","author":"Barresi","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omto.2022.09.009_bib60","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.omtn.2018.11.007","article-title":"Antisense oligonucleotides targeting angiogenic factors as potential cancer therapeutics","volume":"14","author":"Le","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omto.2022.09.009_bib61","doi-asserted-by":"crossref","first-page":"605380","DOI":"10.3389\/fonc.2020.605380","article-title":"Strategies for targeting gene therapy in cancer cells with tumor-specific promoters","volume":"10","author":"Monta\u00f1o-Samaniego","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omto.2022.09.009_bib62","doi-asserted-by":"crossref","first-page":"790150","DOI":"10.3389\/fcell.2021.790150","article-title":"Oncolytic virotherapy: from bench to bedside","volume":"9","author":"Yang","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.omto.2022.09.009_bib63","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s42003-022-03041-4","article-title":"Carvedilol targets beta-arrestins to rewire innate immunity and improve oncolytic adenoviral therapy","volume":"5","author":"Hoare","year":"2022","journal-title":"Commun. Biol."},{"key":"10.1016\/j.omto.2022.09.009_bib64","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.omto.2021.12.016","article-title":"Oncolytic vaccinia virus injected intravenously sensitizes pancreatic neuroendocrine tumors and metastases to immune checkpoint blockade","volume":"24","author":"Inoue","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omto.2022.09.009_bib65","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12985-014-0223-y","article-title":"Oncolytic parvoviruses: from basic virology to clinical applications","volume":"12","author":"Marchini","year":"2015","journal-title":"Virol. J."},{"key":"10.1016\/j.omto.2022.09.009_bib66","doi-asserted-by":"crossref","first-page":"e1001141","DOI":"10.1371\/journal.ppat.1001141","article-title":"Parvovirus minute virus of mice induces a DNA damage response that facilitates viral replication","volume":"6","author":"Adeyemi","year":"2010","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.omto.2022.09.009_bib67","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/ijc.25168","article-title":"Parvovirus H1 selectively induces cytotoxic effects on human neuroblastoma cells","volume":"127","author":"Lacroix","year":"2010","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.omto.2022.09.009_bib68","doi-asserted-by":"crossref","first-page":"5909","DOI":"10.1128\/JVI.01797-09","article-title":"Through its nonstructural protein NS1, parvovirus H-1 induces apoptosis via accumulation of reactive oxygen species","volume":"84","author":"Hristov","year":"2010","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omto.2022.09.009_bib69","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00441-006-0199-z","article-title":"Oncolytic murine autonomous parvovirus, a candidate vector for glioma gene therapy, is innocuous to normal and immunocompetent mouse glial cells","volume":"325","author":"Abschuetz","year":"2006","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.omto.2022.09.009_bib70","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1158\/1078-0432.CCR-11-2325","article-title":"Molecular pathways: rodent parvoviruses--mechanisms of oncolysis and prospects for clinical cancer treatment","volume":"18","author":"N\u00fcesch","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omto.2022.09.009_bib71","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/cgt.2012.20","article-title":"Activation of a glioma-specific immune response by oncolytic parvovirus Minute Virus of Mice infection","volume":"19","author":"Grekova","year":"2012","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.omto.2022.09.009_bib72","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1146\/annurev-virology-012220-023606","article-title":"A roadmap for the success of oncolytic parvovirus-based anticancer therapies","volume":"7","author":"Hartley","year":"2020","journal-title":"Annu. Rev. Virol."},{"key":"10.1016\/j.omto.2022.09.009_bib73","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s40259-020-00453-8","article-title":"Focused update on AAV-based gene therapy clinical trials for inherited retinal degeneration","volume":"34","author":"Fuller-Carter","year":"2020","journal-title":"BioDrugs."},{"key":"10.1016\/j.omto.2022.09.009_bib74","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3390\/cells11030417","article-title":"Restoring SMN expression: an overview of the therapeutic developments for the treatment of spinal muscular atrophy","volume":"11","author":"Aslesh","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.omto.2022.09.009_bib75","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1080\/10428194.2017.1387905","article-title":"Axicabtagene ciloleucel, a first-in-class CAR T\u00a0cell therapy for aggressive NHL","volume":"59","author":"Roberts","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.omto.2022.09.009_bib76","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s41669-018-0102-3","article-title":"Strimvelis((R)) for treating severe combined immunodeficiency caused by adenosine deaminase deficiency: an evidence review group perspective of a NICE highly specialised technology evaluation","volume":"3","author":"South","year":"2019","journal-title":"Pharmacoecon. Open"},{"key":"10.1016\/j.omto.2022.09.009_bib77","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1038\/mt.2012.194","article-title":"Glybera finally recommended for approval as the first gene therapy drug in the European Union","volume":"20","author":"Yl\u00e4-Herttuala","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omto.2022.09.009_bib78","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1586\/17512433.2014.852065","article-title":"Safety profile of recombinant adeno-associated viral vectors: focus on alipogene tiparvovec (Glybera(R))","volume":"7","author":"Salmon","year":"2014","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"10.1016\/j.omto.2022.09.009_bib79","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/sj.gt.3301885","article-title":"ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties","volume":"10","author":"Liu","year":"2003","journal-title":"Gene Ther."},{"key":"10.1016\/j.omto.2022.09.009_bib80","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/978-1-61779-095-9_14","article-title":"Manufacture of measles viruses","volume":"737","author":"Langfield","year":"2011","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.omto.2022.09.009_bib81","doi-asserted-by":"crossref","first-page":"16018","DOI":"10.1038\/mtm.2016.18","article-title":"Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses","volume":"3","author":"Ungerechts","year":"2016","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omto.2022.09.009_bib82","doi-asserted-by":"crossref","first-page":"544","DOI":"10.3390\/cancers13030544","article-title":"Measles virus as an oncolytic immunotherapy","volume":"13","author":"Engeland","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.omto.2022.09.009_bib83","doi-asserted-by":"crossref","first-page":"e001486","DOI":"10.1136\/jitc-2020-001486","article-title":"Clinical landscape of oncolytic virus research in 2020","volume":"8","author":"Macedo","year":"2020","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.omto.2022.09.009_bib84","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/sj.cr.7310019","article-title":"Antiviral innate immunity pathways","volume":"16","author":"Seth","year":"2006","journal-title":"Cell Res."},{"key":"10.1016\/j.omto.2022.09.009_bib85","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/jgm.940","article-title":"Humoral immune responses against minute virus of mice vectors","volume":"8","author":"Lang","year":"2006","journal-title":"J.\u00a0Gene Med."},{"key":"10.1016\/j.omto.2022.09.009_bib86","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2174\/1566523034578285","article-title":"From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy","volume":"3","author":"Grimm","year":"2003","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.omto.2022.09.009_bib87","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.1128\/JVI.73.5.3994-4003.1999","article-title":"Gene therapy vectors based on adeno-associated virus type 1","volume":"73","author":"Xiao","year":"1999","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omto.2022.09.009_bib88","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1089\/hum.2016.055","article-title":"High-density recombinant adeno-associated viral particles are competent vectors for in\u00a0vivo transduction","volume":"27","author":"Wang","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omto.2022.09.009_bib89","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.ymthe.2006.05.009","article-title":"Adeno-associated virus serotypes: vector toolkit for human gene therapy","volume":"14","author":"Wu","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omto.2022.09.009_bib90","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s11095-007-9431-0","article-title":"Designer gene delivery vectors: molecular engineering and evolution of adeno-associated viral vectors for enhanced gene transfer","volume":"25","author":"Kwon","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.omto.2022.09.009_bib91","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1089\/hum.2021.124","article-title":"Chemical modifications of the capsid for redirecting and improving the efficacy of adeno-associated virus vectors","volume":"32","author":"Lam","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omto.2022.09.009_bib92","doi-asserted-by":"crossref","first-page":"e1006929","DOI":"10.1371\/journal.ppat.1006929","article-title":"Creating an arsenal of Adeno-associated virus (AAV) gene delivery stealth vehicles","volume":"14","author":"Smith","year":"2018","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.omto.2022.09.009_bib93","doi-asserted-by":"crossref","first-page":"e104596","DOI":"10.1371\/journal.pone.0104596","article-title":"The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication","volume":"9","author":"Cao","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.omto.2022.09.009_bib94","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1089\/hgtb.2019.276","article-title":"A user's guide to the inverted terminal repeats of adeno-associated virus","volume":"30","author":"Wilmott","year":"2019","journal-title":"Hum. Gene Ther. Methods"},{"key":"10.1016\/j.omto.2022.09.009_bib95","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/d41573-021-00017-7","article-title":"The clinical landscape for AAV gene therapies","volume":"20","author":"Kuzmin","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omto.2022.09.009_bib96","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1172\/JCI200316887","article-title":"Induction of immune tolerance to coagulation factor IX antigen by in\u00a0vivo hepatic gene transfer","volume":"111","author":"Mingozzi","year":"2003","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omto.2022.09.009_bib97","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.3390\/jcm10112471","article-title":"Emerging immunogenicity and genotoxicity considerations of adeno-associated virus vector gene therapy for hemophilia","volume":"10","author":"Monahan","year":"2021","journal-title":"J.\u00a0Clin. Med."},{"key":"10.1016\/j.omto.2022.09.009_bib98","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1089\/hum.2017.016","article-title":"Gene delivery of activated factor VII using alternative adeno-associated virus serotype improves hemostasis in hemophiliac mice with FVIII inhibitors and adeno-associated virus neutralizing antibodies","volume":"28","author":"Sun","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omto.2022.09.009_bib99","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1038\/s41388-021-01725-5","article-title":"Large-scale molecular epidemiological analysis of AAV in a cancer patient population","volume":"40","author":"Qin","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.omto.2022.09.009_bib100","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/mt.2016.52","article-title":"Recombinant AAV integration is not associated with hepatic genotoxicity in nonhuman primates and patients","volume":"24","author":"Gil-Farina","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omto.2022.09.009_bib101","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3389\/fcell.2020.00210","article-title":"Intra-tumoral delivery of IL-27 using adeno-associated virus stimulates anti-tumor immunity and enhances the efficacy of immunotherapy","volume":"8","author":"Hu","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.omto.2022.09.009_bib102","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/cgt.2017.12","article-title":"Preclinical study of rAAV2-sTRAIL: pharmaceutical efficacy, biodistribution and safety in animals","volume":"24","author":"Ru","year":"2017","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.omto.2022.09.009_bib103","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s11060-018-2889-2","article-title":"Virus vector-mediated genetic modification of brain tumor stromal cells after intravenous delivery","volume":"139","author":"Volak","year":"2018","journal-title":"J.\u00a0Neurooncol."},{"key":"10.1016\/j.omto.2022.09.009_bib104","doi-asserted-by":"crossref","first-page":"672449","DOI":"10.3389\/fimmu.2021.672449","article-title":"Effect of CpG depletion of vector genome on CD8(+) T\u00a0cell responses in AAV gene therapy","volume":"12","author":"Bertolini","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omto.2022.09.009_bib105","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.ymthe.2019.11.006","article-title":"A molecular revolution in the treatment of hemophilia","volume":"28","author":"Butterfield","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omto.2022.09.009_bib106","doi-asserted-by":"crossref","first-page":"975803","DOI":"10.3389\/fimmu.2022.975803","article-title":"Immunogenicity and toxicity of AAV gene therapy","volume":"13","author":"Ertl","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omto.2022.09.009_bib107","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/gt.2012.20","article-title":"Directed evolution of novel adeno-associated viruses for therapeutic gene delivery","volume":"19","author":"Bartel","year":"2012","journal-title":"Gene Ther."},{"key":"10.1016\/j.omto.2022.09.009_bib108","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1358\/dot.2021.57.6.3264117","article-title":"Onasemnogene abeparvovec-xioi: a gene replacement strategy for the treatment of infants diagnosed with spinal muscular atrophy","volume":"57","author":"Schwartz","year":"2021","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.omto.2022.09.009_bib109","doi-asserted-by":"crossref","first-page":"100759","DOI":"10.1016\/j.blre.2020.100759","article-title":"Discussing investigational AAV gene therapy with hemophilia patients: a guide","volume":"47","author":"Sidonio","year":"2021","journal-title":"Blood Rev."},{"key":"10.1016\/j.omto.2022.09.009_bib110","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1006\/mthe.2001.0456","article-title":"Expanding AAV packaging capacity with trans-splicing or overlapping vectors: a quantitative comparison","volume":"4","author":"Duan","year":"2001","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omto.2022.09.009_bib111","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/mt.2012.283","article-title":"Microdystrophin ameliorates muscular dystrophy in the canine model of duchenne muscular dystrophy","volume":"21","author":"Shin","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omto.2022.09.009_bib112","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.3892\/or.2012.1621","article-title":"AAV-mediated gene transfer of human pigment epithelium-derived factor inhibits Lewis lung carcinoma growth in mice","volume":"27","author":"He","year":"2012","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.omto.2022.09.009_bib113","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41417-019-0137-3","article-title":"Specific driving of the suicide E gene by the CEA promoter enhances the effects of paclitaxel in lung cancer","volume":"27","author":"Rama Ballesteros","year":"2020","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.omto.2022.09.009_bib114","first-page":"1931","article-title":"Efficacy of recombinant adeno-associated viral vectors serotypes 1, 2, and 5 for the transduction of pancreatic and colon carcinoma cells","volume":"30","author":"Teschendorf","year":"2010","journal-title":"Anticancer Res."},{"key":"10.1016\/j.omto.2022.09.009_bib115","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3748\/wjg.v22.i1.326","article-title":"Targeting adeno-associated virus and adenoviral gene therapy for hepatocellular carcinoma","volume":"22","author":"Wang","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.omto.2022.09.009_bib116","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/gt.2015.89","article-title":"Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells","volume":"23","author":"Sayroo","year":"2016","journal-title":"Gene Ther."},{"key":"10.1016\/j.omto.2022.09.009_bib117","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/gt.2015.76","article-title":"Treatment of multifocal breast cancer by systemic delivery of dual-targeted adeno-associated viral vectors","volume":"22","author":"Trepel","year":"2015","journal-title":"Gene Ther."},{"key":"10.1016\/j.omto.2022.09.009_bib118","doi-asserted-by":"crossref","first-page":"13891","DOI":"10.1073\/pnas.94.25.13891","article-title":"Tissue-specific expression of herpes simplex virus thymidine kinase gene delivered by adeno-associated virus inhibits the growth of human hepatocellular carcinoma in athymic mice","volume":"94","author":"Su","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omto.2022.09.009_bib119","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1089\/hum.1996.7.4-463","article-title":"Selective killing of AFP-positive hepatocellular carcinoma cells by adeno-associated virus transfer of the herpes simplex virus thymidine kinase gene","volume":"7","author":"Su","year":"1996","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omto.2022.09.009_bib120","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3390\/cancers14020427","article-title":"Hepatocellular carcinoma is a natural target for adeno-associated virus (AAV) 2 vectors","volume":"14","author":"Meumann","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.omto.2022.09.009_bib121","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ymgme.2009.05.010","article-title":"AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells","volume":"98","author":"Glushakova","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.omto.2022.09.009_bib122","doi-asserted-by":"crossref","first-page":"16017","DOI":"10.1038\/mto.2016.17","article-title":"Systemically administered AAV9-sTRAIL combats invasive glioblastoma in a patient-derived orthotopic xenograft model","volume":"3","author":"Crommentuijn","year":"2016","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omto.2022.09.009_bib123","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1002\/1878-0261.12787","article-title":"AAV-mediated gene transfer of DNase I in the liver of mice with colorectal cancer reduces liver metastasis and restores local innate and adaptive immune response","volume":"14","author":"Xia","year":"2020","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.omto.2022.09.009_bib124","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.3892\/or.2012.1915","article-title":"AAV2-mediated gene transfer of VEGF-Trap with potent suppression of primary breast tumor growth and spontaneous pulmonary metastases by long-term expression","volume":"28","author":"Lu","year":"2012","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.omto.2022.09.009_bib125","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2174\/1566523044578077","article-title":"Promoters and control elements: designing expression cassettes for gene therapy","volume":"4","author":"Papadakis","year":"2004","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.omto.2022.09.009_bib126","doi-asserted-by":"crossref","first-page":"6901","DOI":"10.1158\/0008-5472.CAN-05-0408","article-title":"Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor","volume":"65","author":"Lin","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.omto.2022.09.009_bib127","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1038\/s41388-021-01742-4","article-title":"FOXP1 drives osteosarcoma development by repressing P21 and RB transcription downstream of P53","volume":"40","author":"Li","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.omto.2022.09.009_bib128","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1007\/s12094-021-02590-0","article-title":"Blinatumomab to improve the outcome of children with relapsed B-cell acute lymphoblastic leukemia","volume":"23","author":"Fuster","year":"2021","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.omto.2022.09.009_bib129","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.actbio.2019.04.044","article-title":"Anti-EpCAM-conjugated adeno-associated virus serotype 2 for systemic delivery of EGFR shRNA: its retargeting and antitumor effects on OVCAR3 ovarian cancer in\u00a0vivo","volume":"91","author":"Lee","year":"2019","journal-title":"Acta Biomater."},{"key":"10.1016\/j.omto.2022.09.009_bib130","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s11914-016-0315-2","article-title":"The bone microenvironment: a fertile soil for tumor growth","volume":"14","author":"Buenrostro","year":"2016","journal-title":"Curr. Osteoporos. Rep."},{"key":"10.1016\/j.omto.2022.09.009_bib131","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.omto.2022.09.009_bib132","first-page":"321","article-title":"Bone metastases: an overview","volume":"11","author":"Macedo","year":"2017","journal-title":"Oncol. Rev."},{"key":"10.1016\/j.omto.2022.09.009_bib133","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.3390\/cancers13122887","article-title":"Mechanisms supporting the use of beta-blockers for the management of breast cancer bone metastasis","volume":"13","author":"Madel","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.omto.2022.09.009_bib134","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.bone.2010.07.015","article-title":"Advances in the biology of bone metastasis: how the skeleton affects tumor behavior","volume":"48","author":"Sterling","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.omto.2022.09.009_bib135","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1158\/0008-5472.CAN-19-0458","article-title":"Defining the hallmarks of metastasis","volume":"79","author":"Welch","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.omto.2022.09.009_bib136","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12916-017-0900-y","article-title":"The role of tumour heterogeneity and clonal cooperativity in metastasis, immune evasion and clinical outcome","volume":"15","author":"Caswell","year":"2017","journal-title":"BMC Med."},{"key":"10.1016\/j.omto.2022.09.009_bib137","doi-asserted-by":"crossref","first-page":"12097","DOI":"10.18632\/oncotarget.2503","article-title":"E-selectin ligand-1 controls circulating prostate cancer cell rolling\/adhesion and metastasis","volume":"5","author":"Yasmin-Karim","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.omto.2022.09.009_bib138","doi-asserted-by":"crossref","first-page":"693","DOI":"10.3892\/ol.2021.12954","article-title":"Identification of differentially expressed genes using microarray analysis and COL6A1 induction of bone metastasis in non-small cell lung cancer","volume":"22","author":"Li","year":"2021","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.omto.2022.09.009_bib139","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/cr.2012.89","article-title":"Global secretome analysis identifies novel mediators of bone metastasis","volume":"22","author":"Blanco","year":"2012","journal-title":"Cell Res."},{"key":"10.1016\/j.omto.2022.09.009_bib140","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/cgt.2012.38","article-title":"HGFK1 inhibits bone metastasis in breast cancer through the TAK1\/p38 MAPK signaling pathway","volume":"19","author":"Yao","year":"2012","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.omto.2022.09.009_bib141","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/nm1447","article-title":"Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma","volume":"12","author":"Thaker","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.omto.2022.09.009_bib142","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s10555-012-9372-x","article-title":"Genes associate with abnormal bone cell activity in bone metastasis","volume":"31","author":"Roodman","year":"2012","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.omto.2022.09.009_bib143","doi-asserted-by":"crossref","first-page":"100330","DOI":"10.1016\/j.jbo.2020.100330","article-title":"The HMGB1\/RAGE axis induces bone pain associated with colonization of 4T1 mouse breast cancer in bone","volume":"26","author":"Okui","year":"2021","journal-title":"J.\u00a0Bone Oncol."},{"key":"10.1016\/j.omto.2022.09.009_bib144","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.biomaterials.2015.06.026","article-title":"Matrix rigidity regulates the transition of tumor cells to a bone-destructive phenotype through integrin beta3 and TGF-beta receptor type II","volume":"64","author":"Page","year":"2015","journal-title":"Biomaterials"},{"key":"10.1016\/j.omto.2022.09.009_bib145","doi-asserted-by":"crossref","first-page":"E6913","DOI":"10.3390\/ijms21186913","article-title":"3D bone morphology alters gene expression, motility, and drug responses in bone metastatic tumor cells","volume":"21","author":"Dadwal","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omto.2022.09.009_bib146","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/bonekey.2016.75","article-title":"Tissue-engineered 3D cancer-in-bone modeling: silk and PUR protocols","volume":"5","author":"Dadwal","year":"2016","journal-title":"Bonekey Rep."},{"key":"10.1016\/j.omto.2022.09.009_bib147","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/jbmr.3133","article-title":"Skeletal colonization by breast cancer cells is stimulated by an osteoblast and beta2AR-dependent neo-angiogenic switch","volume":"32","author":"Mulcrone","year":"2017","journal-title":"J.\u00a0Bone Miner. Res."},{"key":"10.1016\/j.omto.2022.09.009_bib148","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jbo.2016.03.003","article-title":"Role of sympathetic nerves in the establishment of metastatic breast cancer cells in bone","volume":"5","author":"Elefteriou","year":"2016","journal-title":"J.\u00a0Bone Oncol."},{"key":"10.1016\/j.omto.2022.09.009_bib149","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.3390\/cancers13123070","article-title":"Perspectives on hypoxia signaling in tumor stroma","volume":"13","author":"Zhang","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.omto.2022.09.009_bib150","doi-asserted-by":"crossref","first-page":"6206","DOI":"10.3390\/cancers13246206","article-title":"The colorectal cancer tumor microenvironment and its impact on liver and lung metastasis","volume":"13","author":"Chandra","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.omto.2022.09.009_bib151","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.gde.2004.12.003","article-title":"Tumor-stroma interactions","volume":"15","author":"Bhowmick","year":"2005","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.omto.2022.09.009_bib152","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41577-020-0275-8","article-title":"Dissecting the mechanisms of immune checkpoint therapy","volume":"20","author":"Sharma","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.omto.2022.09.009_bib153","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/j.1600-0463.2008.01027.x","article-title":"Tumor-vascular interactions and tumor dormancy","volume":"116","author":"Horak","year":"2008","journal-title":"APMIS"},{"key":"10.1016\/j.omto.2022.09.009_bib154","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1158\/1535-7163.MCT-12-1123","article-title":"PG545, an angiogenesis and heparanase inhibitor, reduces primary tumor growth and metastasis in experimental pancreatic cancer","volume":"12","author":"Ostapoff","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.omto.2022.09.009_bib155","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.2174\/1389450117666151209123544","article-title":"The challenges of modeling drug resistance to antiangiogenic therapy","volume":"17","author":"Mastri","year":"2016","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.omto.2022.09.009_bib156","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41575-020-0300-1","article-title":"Pancreatic cancer stroma: an update on therapeutic targeting strategies","volume":"17","author":"Hosein","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.omto.2022.09.009_bib157","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12951-022-01311-1","article-title":"A CFH peptide-decorated liposomal oxymatrine inactivates cancer-associated fibroblasts of hepatocellular carcinoma through epithelial-mesenchymal transition reversion","volume":"20","author":"Guo","year":"2022","journal-title":"J.\u00a0Nanobiotechnology"},{"key":"10.1016\/j.omto.2022.09.009_bib158","doi-asserted-by":"crossref","first-page":"4031","DOI":"10.7314\/APJCP.2012.13.8.4031","article-title":"Reconstructed adeno-associated virus with the extracellular domain of murine PD-1 induces antitumor immunity","volume":"13","author":"Elhag","year":"2012","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.omto.2022.09.009_bib159","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.omto.2021.01.010","article-title":"Eliminating mesothelioma by AAV-vectored, PD1-based vaccination in the tumor microenvironment","volume":"20","author":"Tan","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omto.2022.09.009_bib160","doi-asserted-by":"crossref","first-page":"11655","DOI":"10.1128\/JVI.01040-09","article-title":"Adeno-associated virus site-specific integration is mediated by proteins of the nonhomologous end-joining pathway","volume":"83","author":"Daya","year":"2009","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omto.2022.09.009_bib161","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood-2003-05-1446","article-title":"Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1","volume":"103","author":"Arruda","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.omto.2022.09.009_bib162","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1089\/hum.2007.0182","article-title":"Complete correction of hemophilia A with adeno-associated viral vectors containing a full-size expression cassette","volume":"19","author":"Lu","year":"2008","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omto.2022.09.009_bib163","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/6807904","article-title":"Genomic designs of rAAVs contribute to pathological changes in the livers and spleens of mice. Article","author":"Mulcrone","year":"2022","journal-title":"Adv. Cell Gene Ther."},{"key":"10.1016\/j.omto.2022.09.009_bib164","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ymthe.2004.05.024","article-title":"Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system","volume":"10","author":"Burger","year":"2004","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omto.2022.09.009_bib165","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/mt.2008.76","article-title":"Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection","volume":"16","author":"Zincarelli","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omto.2022.09.009_bib166","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1089\/hum.2010.245","article-title":"Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors","volume":"22","author":"Gray","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omto.2022.09.009_bib167","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1136\/gutjnl-2019-318281","article-title":"Adeno-associated virus in the liver: natural history and consequences in tumour development","volume":"69","author":"La Bella","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.omto.2022.09.009_bib168","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1089\/hgtb.2014.093","article-title":"Efficient production of dual recombinant adeno-associated viral vectors for factor VIII delivery","volume":"25","author":"Wang","year":"2014","journal-title":"Hum. Gene Ther. Methods"},{"key":"10.1016\/j.omto.2022.09.009_bib169","doi-asserted-by":"crossref","first-page":"881","DOI":"10.3324\/haematol.2014.123117","article-title":"Extrahepatic sources of factor VIII potentially contribute to the coagulation cascade correcting the bleeding phenotype of mice with hemophilia A","volume":"100","author":"Zanolini","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.omto.2022.09.009_bib170","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/gt.2016.34","article-title":"Evaluation of the biological differences of canine and human factor VIII in gene delivery: implications in human hemophilia treatment","volume":"23","author":"Wang","year":"2016","journal-title":"Gene Ther."},{"key":"10.1016\/j.omto.2022.09.009_bib171","first-page":"110","article-title":"Transcriptional targeting in cancer gene therapy","volume":"2003","author":"Robson","year":"2003","journal-title":"J.\u00a0Biomed. Biotechnol."},{"key":"10.1016\/j.omto.2022.09.009_bib172","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.cell.2009.04.021","article-title":"Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model","volume":"137","author":"Kota","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.omto.2022.09.009_bib173","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.canlet.2011.01.001","article-title":"Adeno-associated virus-mediated anti-DR5 chimeric antibody expression suppresses human tumor growth in nude mice","volume":"302","author":"Lv","year":"2011","journal-title":"Cancer Lett."},{"key":"10.1016\/j.omto.2022.09.009_bib174","doi-asserted-by":"crossref","first-page":"49008","DOI":"10.18632\/oncotarget.10264","article-title":"Identification of IFN-gamma-producing T\u00a0cells as the main mediators of the side effects associated to mouse interleukin-15 sustained exposure","volume":"7","author":"Di Scala","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.omto.2022.09.009_bib175","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1471-2407-11-54","article-title":"Synergistic antitumor effect of AAV-mediated TRAIL expression combined with cisplatin on head and neck squamous cell carcinoma","volume":"11","author":"Jiang","year":"2011","journal-title":"BMC Cancer"}],"container-title":["Molecular Therapy - Oncolytics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770522001218?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770522001218?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:25:00Z","timestamp":1762496700000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2372770522001218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":175,"alternative-id":["S2372770522001218"],"URL":"https:\/\/doi.org\/10.1016\/j.omto.2022.09.009","relation":{},"ISSN":["2372-7705"],"issn-type":[{"value":"2372-7705","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adding recombinant AAVs to the cancer therapeutics mix","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Oncolytics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omto.2022.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors.","name":"copyright","label":"Copyright"}]}}